Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as Treatment for Advanced Squamous Non–Small-Cell Lung Cancer - For The Media

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, APRIL 1, 2021

Media advisory: The full article and commentary are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.0366?guestAccessKey=555e2943-4aa6-4726-bf66-459cbc8fbf9d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040121

Visual Abstract

Authors: Jie Wang, M.D., Ph.D., of the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, is the corresponding author.

(doi:10.1001/jamaoncol.2021.0366)

Editor’s Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.